Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT05404074
- Locations
- 🇸🇪
CTC, Clinical Trial Consultants AB, Uppsala, Sweden
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Phase 3
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT04985968
- Locations
- ðŸ‡ðŸ‡·
Opca bolnica Bjelovar, Bjelovar, Croatia
ðŸ‡ðŸ‡·University Hospital Centre Zagreb, Zagreb, Croatia
ðŸ‡ðŸ‡·Clinical Hospital Osijek, Osijek, Croatia
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 213
- Registration Number
- NCT03178669
- Locations
- 🇷🇺
34, Cheboksary, Russian Federation
🇺🇦53, Dnipropetrovs'k, Ukraine
🇺🇦56, Kiev, Ukraine
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 131
- Registration Number
- NCT01493960
- Locations
- 🇵🇱
Site 604, Krakow, Poland
🇬🇧Site 101, Nottingham, United Kingdom
🇨🇿Site 406, Ostrava, Czechia
© Copyright 2025. All Rights Reserved by MedPath